Patents by Inventor Gerald D. Cagle
Gerald D. Cagle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368072Abstract: Provided herein are compositions and methods of providing an effective amount of an N-acetylcysteine amide (NACA) or diNACA sufficient to increase the concentration of NACA or diNACA in the affected tissue to biochemically reduce oxidative stress-related damage to tissue; utilizing NACA or diNACA that comprises at least one of impurities B1 or B2, which are indicative of NACA or diNACA manufactured by a process comprising: contacting cystine with methanol and a chlorinating reagent to form an organic solution containing cystine dimethylester dihydrochloride and optionally isolating and drying the cystine dimethylester dihydrochloride; combining the dried or undried cystine dimethylester dihydrochloride with triethylamine, acetic anhydride, and acetonitrile to form di-N-acetylcystine dimethylester; mixing the di-N-acetylcystine dimethylester with ammonium hydroxide to form di-N-acetylcystine amide (diNACA or NPI-002); and reducing the di-N-acetylcystine amide to N-acetylcysteine, NACA or NPI-001 with a reducinType: ApplicationFiled: July 12, 2024Publication date: November 7, 2024Inventors: G. Michael Wall, Gerald D. Cagle
-
Publication number: 20240342118Abstract: Provided herein are compositions and methods of providing an effective amount of an N-acetylcysteine amide (NACA) or diNACA sufficient to increase the concentration of NACA or diNACA in the affected tissue to biochemically reduce oxidative stress-related damage to tissue; utilizing NACA or diNACA that comprises at least one of impurities B1 or B2, which are indicative of NACA or diNACA manufactured by a process comprising: contacting cystine with methanol and a chlorinating reagent to form an organic solution containing cystine dimethylester dihydrochloride and optionally isolating and drying the cystine dimethylester dihydrochloride; combining the dried or undried cystine dimethylester dihydrochloride with triethylamine, acetic anhydride, and acetonitrile to form di-N-acetylcystine dimethylester; mixing the di-N-acetylcystine dimethylester with ammonium hydroxide to form di-N-acetylcystine amide (diNACA or NPI-002); and reducing the di-N-acetylcystine amide to N-acetylcysteine, NACA or NPI-001 with a reducinType: ApplicationFiled: May 30, 2024Publication date: October 17, 2024Inventors: G. Michael Wall, Doug G. Johnson, Anja Rubenstein, Rodney Tucker, Josh Bolger, Marcin Jakub Kowalczyk, Craig Sheehan, Gerald D. Cagle
-
Patent number: 12097188Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.Type: GrantFiled: September 1, 2023Date of Patent: September 24, 2024Assignee: Aldeyra Therapeutics, Inc.Inventors: Thomas A. Jordan, John Clifford Chabala, Gerald D. Cagle
-
Publication number: 20240148700Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.Type: ApplicationFiled: September 1, 2023Publication date: May 9, 2024Inventors: Thomas A. Jordan, John Clifford CHABALA, Gerald D. CAGLE
-
Patent number: 10350309Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.Type: GrantFiled: January 8, 2018Date of Patent: July 16, 2019Assignee: Cognoptix, Inc.Inventors: Haresh Bhagat, Gerald D. Cagle, Francis X. Smith, Paul D. Hartung
-
Publication number: 20180126008Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: January 8, 2018Publication date: May 10, 2018Inventors: Haresh Bhagat, Gerald D. Cagle, Francis X. Smith, Paul D. Hartung
-
Publication number: 20180092882Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.Type: ApplicationFiled: October 12, 2017Publication date: April 5, 2018Inventors: Thomas A. Jordan, John Clifford Chabala, Gerald D. Cagle
-
Patent number: 9814701Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.Type: GrantFiled: December 9, 2010Date of Patent: November 14, 2017Assignee: Aldeyra Therapeutics, Inc.Inventors: Thomas A. Jordan, John Clifford Chabala, Gerald D. Cagle
-
Publication number: 20170172974Abstract: A method of delivering a nasal spray. A sprayer having a formulation comprising olopatadine is provided. A spray of the formulation is delivered to a subject's nose. The spray may have a spray characteristic comprising a spray pattern having a longest axis of 20-45 mm, a shortest axis of 14-20 mm, and an ellipticity of 1-1.8. The spray may also have a spray characteristic comprising a droplet size distribution having a D10 of 15-30 ?m, a D50 of 30-60 ?m, a D90 of 50-150 ?m, a SPAN of not more than 3, and a % Volume of <10 ?m of less than 4%.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Inventors: Gerald D. Cagle, G. Michael Wall
-
Patent number: 9451909Abstract: In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.Type: GrantFiled: December 1, 2015Date of Patent: September 27, 2016Assignee: Cognoptix, Inc.Inventors: Paul D. Hartung, Vincent Valvo, Charles Kerbage, Gerald D. Cagle, Dennis J. Nilan
-
Publication number: 20160183859Abstract: In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.Type: ApplicationFiled: December 1, 2015Publication date: June 30, 2016Inventors: Paul D. Hartung, Vincent Valvo, Charles Kerbage, Gerald D. Cagle, Dennis J. Nilan
-
Patent number: 9220403Abstract: In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.Type: GrantFiled: August 12, 2011Date of Patent: December 29, 2015Assignee: Cognoptix, Inc.Inventors: Paul D. Hartung, Vincent Valvo, Charles Kerbage, Gerald D. Cagle, Dennis J. Nilan
-
Publication number: 20150118163Abstract: The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: October 30, 2014Publication date: April 30, 2015Inventors: Haresh Bhagat, Gerald D. Cagle, Francis X. Smith, Paul D. Hartung
-
Publication number: 20140227326Abstract: A method of delivering a nasal spray. A sprayer having a formulation comprising olopatadine is provided. A spray of the formulation is delivered to a subject's nose. The spray may have a spray characteristic comprising a spray pattern having a longest axis of 20-45 mm, a shortest axis of 14-20 mm, and an ellipticity of 1-1.8. The spray may also have a spray characteristic comprising a droplet size distribution having a D10 of 15-30 ?m, a D50 of 30-60 ?m, a D90 of 50-150 ?m, a SPAN of not more than 3, and a % Volume of <10 ?m of less than 4%.Type: ApplicationFiled: November 14, 2013Publication date: August 14, 2014Applicant: Novartis AGInventors: Gerald D. Cagle, G. Michael Wall
-
Publication number: 20130135580Abstract: In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.Type: ApplicationFiled: August 12, 2011Publication date: May 30, 2013Inventors: Paul D. Hartung, Vincent Valvo, Charles Kerbage, Gerald D. Cagle, Dennis J. Nilan
-
Publication number: 20120302601Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.Type: ApplicationFiled: December 9, 2010Publication date: November 29, 2012Applicant: Neuron Systems, Inc.Inventors: Thomas A. Jordan, John Clifford Chabala, Gerald D. Cagle
-
Patent number: 8080028Abstract: A surgical knife blade or other surgical device containing an anti-microbial coating. The coating may be adhered to the device by a water-soluble adhesive that allows the anti-microbial coating to be released into the wound track. The coating may be of a consistency that allows a certain amount of the coating to slough off and pool or puddle around the surgical site as the surgical device is moved into and out of the surgical site.Type: GrantFiled: December 5, 2005Date of Patent: December 20, 2011Assignee: Novartis AGInventor: Gerald D. Cagle
-
Publication number: 20040126436Abstract: Compositions for assisting in the removal of human cerumen are disclosed. The compositions may include bicarbonate and an otologically acceptable vehicle; a cerumenolytically acceptable enzyme and an otologically acceptable vehicle; or bicarbonate, a cerumenolytically acceptable enzyme, and an otologically acceptable vehicle.Type: ApplicationFiled: November 10, 2003Publication date: July 1, 2004Inventors: Gerald D. Cagle, Geoffrey R. Owen, Nuria Jimenez Ridruejo, G. Michael Wall
-
Publication number: 20040097474Abstract: Compositions and methods for treating rhinitis with certain combinations of antiallergic agents and steroids are disclosed.Type: ApplicationFiled: November 12, 2003Publication date: May 20, 2004Applicant: Alcon, Inc.Inventors: Gerald D. Cagle, G. Michael Wall, John M. Yanni, Rajni Jani, Haresh G. Bhagat
-
Publication number: 20040033208Abstract: Antimicrobial compositions containing one or more topically active antibiotics (e.g., Natamycin) and one or more amidoamines are described. The amidoamines enhance or supplement the antimicrobial activity of natamycin or other topically active antibiotics. The compositions are particularly useful in treating or preventing fungal infections of the eye, ear, nose and throat, as well as sterilizing these tissues prior to surgery or other medical procedures.Type: ApplicationFiled: May 22, 2003Publication date: February 19, 2004Inventors: Gerald D. Cagle, Barry A. Schlech, Joseph W. Hiddene, G. Michael Wall